DNA 리가아제 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of DNA ligases Market

The global DNA ligases market was valued at USD 378.22 million in 2025 and is projected to grow from USD 411.2 million in 2026 to USD 830.46 million by 2034, registering a CAGR of 9.18% during the forecast period. North America dominated the market with a 51.21% share in 2025, driven by strong biotechnology infrastructure, increasing gene therapy research, and rapid adoption of gene editing tools.

Market Overview

DNA ligases are essential enzymes that catalyze the formation of phosphodiester bonds between DNA fragments, enabling DNA repair, replication, and recombination. In molecular biology and biotechnology industries, these enzymes are widely used for DNA cloning, next-generation sequencing (NGS) library preparation, gene synthesis, and genome editing.

The market is witnessing steady expansion due to advancements in genetic engineering, synthetic biology, genomics research, and increasing demand for cell and gene therapies. Leading players such as Thermo Fisher Scientific Inc., Takara Bio Inc., and New England Biolabs hold significant shares due to their extensive product portfolios and global distribution networks.

Market Dynamics

Market Drivers

Advancements in Gene Editing Technologies

The rapid evolution of gene editing technologies, particularly CRISPR-Cas9, is a major growth driver. DNA ligases play a crucial role in repairing DNA strands during gene manipulation processes. As CRISPR-based therapies gain traction in oncology, genetic disorders, and autoimmune diseases, demand for high-efficiency ligases continues to rise.

In September 2024, KSQ Therapeutics received U.S. FDA clearance to initiate a Phase 1/2 clinical trial for its CRISPR-engineered TIL therapy candidate, highlighting increasing clinical applications that rely on DNA ligases.

Market Restraints

Technical Complications and Skilled Workforce Shortage

Despite strong growth potential, off-target effects in gene editing raise safety and regulatory concerns. Articles published in early 2024 highlight limitations of CRISPR due to unintended genomic modifications. Additionally, challenges in designing delivery systems, scaling enzyme production, and the shortage of skilled professionals may restrain market expansion.

Market Opportunities

Strategic Collaborations and Expansions

Companies are actively pursuing mergers, acquisitions, and partnerships to expand their genomic technology portfolios. For example, in September 2021, Fortis Life Sciences acquired Empirical Bioscience to strengthen its recombinant protein and enzyme manufacturing capabilities. Expansion into Asia Pacific markets presents additional growth opportunities.

Market Challenges

High costs of advanced ligase enzymes limit accessibility for small research institutions and developing countries. Moreover, strict regulatory frameworks surrounding genetic engineering tools can slow product approvals and commercialization.

Market Trends

Rising Focus on Cell & Gene Therapies

The growing shift toward personalized medicine and cell-based gene therapies is shaping new market trends. In March 2025, Neurotech Pharmaceuticals received FDA approval for a cell-based gene therapy, underscoring the increasing importance of cloning and gene editing tools, including DNA ligases.

Strategic investments in enzyme innovation and high-efficiency ligase variants are further strengthening the market outlook.

Segmentation Analysis

By Type

The market is segmented into T4 DNA, T7 DNA, and others.

• T4 DNA ligase dominated the market in 2025 due to its high efficiency and versatility in cloning and genetic engineering applications.
• T7 DNA ligase is expected to grow at the highest CAGR through 2034, driven by increasing adoption in synthetic biology and biopharmaceutical research.
• The others segment, including thermostable ligases, is gaining traction in PCR and molecular diagnostics applications.

By Application

The genomics & genetic engineering segment held the largest share in 2025, supported by rapid advancements in CRISPR-based editing and synthetic biology.

The drug discovery & research segment is anticipated to grow at a higher CAGR through 2034, driven by rising investments in personalized medicine and collaborative research initiatives.

Diagnostics applications are also expanding due to growing adoption of PCR and NGS technologies.

By End-User

Pharmaceutical and biotechnology companies accounted for the largest market share in 2025, driven by extensive gene therapy and vaccine development programs.

Academic & research institutes represent a strong secondary segment, supported by increasing funding in genomics research.

The others segment, including CROs and diagnostic laboratories, is expanding due to rising genetic disease prevalence and demand for molecular diagnostics.

Regional Outlook

North America

North America generated USD 193.68 million in 2025, maintaining leadership due to advanced research infrastructure and strategic acquisitions. The U.S. remains the key contributor, supported by rapid adoption of gene editing tools.

Europe

Europe held the second-largest share in 2025, supported by strong academic research and government investments in genomics. Germany and the U.K. lead regional R&D initiatives.

Asia Pacific

Asia Pacific is projected to grow at the highest CAGR through 2034, driven by expanding biotechnology manufacturing and partnerships such as Cytiva's collaboration in China.

Latin America & Middle East & Africa

These regions are witnessing gradual growth due to expanding genomics programs and rising investment in precision medicine. The Saudi Genome Program has significantly accelerated sequencing initiatives in the GCC region.

Competitive Landscape

The market is semi-consolidated with key players including:

• Thermo Fisher Scientific Inc.
• New England Biolabs
• Takara Bio Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Promega Corporation
• Danaher Corporation
• Fortis Life Sciences, LLC.

Strategic investments, manufacturing expansions, and R&D collaborations continue to strengthen competitive positioning.

Conclusion

The global DNA ligases market is poised for substantial growth, expanding from USD 378.22 million in 2025 to USD 830.46 million by 2034, at a CAGR of 9.18%. Rising advancements in gene editing, increasing clinical trials in cell and gene therapies, and expanding genomics research are key growth drivers. While high enzyme costs and regulatory challenges may restrain adoption, strategic collaborations and innovation in high-efficiency ligases are expected to sustain long-term market expansion across global biotechnology and pharmaceutical sectors.

Segmentation By Type

• T7 DNA
• T4 DNA
• Others

By Application

• Genomics & Genetic Engineering
• Drug Discovery & Research
• Others

By End-user

• Pharmaceutical and Biotechnology Companies
• Academic & Research Institutes
• Others

By Region

• North America (By Type, Application, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Type, Application, End-user, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Application, End-user, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Application, End-user, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Application, End-user, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in DNA Modification Techniques
• 4.2. Technological Advancements in Genetic Engineering
• 4.3. New Product Launches, By Key Players
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnership, etc.)
• 4.5. Impact of COVID-19 on the Market

5. Global DNA Ligases Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. T7 DNA
  • 5.1.2. T4 DNA
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Genomics & Genetic Engineering
  • 5.2.2. Drug Discovery & Research
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Pharmaceutical and Biotechnology Companies
  • 5.3.2. Academic & Research Institutes
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America DNA Ligases Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. T7 DNA
  • 6.1.2. T4 DNA
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Genomics & Genetic Engineering
  • 6.2.2. Drug Discovery & Research
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Pharmaceutical and Biotechnology Companies
  • 6.3.2. Academic & Research Institutes
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe DNA Ligases Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. T7 DNA
  • 7.1.2. T4 DNA
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Genomics & Genetic Engineering
  • 7.2.2. Drug Discovery & Research
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Pharmaceutical and Biotechnology Companies
  • 7.3.2. Academic & Research Institutes
  • 7.3.3. Others
• 7.4. Market Analysis, Insights, and Forecast - By Country/Sub-Region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific DNA Ligases Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. T7 DNA
  • 8.1.2. T4 DNA
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Genomics & Genetic Engineering
  • 8.2.2. Drug Discovery & Research
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Pharmaceutical and Biotechnology Companies
  • 8.3.2. Academic & Research Institutes
  • 8.3.3. Others
• 8.4. Market Analysis, Insights, and Forecast - By Country/Sub-Region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America DNA Ligases Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. T7 DNA
  • 9.1.2. T4 DNA
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Genomics & Genetic Engineering
  • 9.2.2. Drug Discovery & Research
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Pharmaceutical and Biotechnology Companies
  • 9.3.2. Academic & Research Institutes
  • 9.3.3. Others
• 9.4. Market Analysis, Insights, and Forecast - By Country/Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East and Africa DNA Ligases Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. T7 DNA
  • 10.1.2. T4 DNA
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Genomics & Genetic Engineering
  • 10.2.2. Drug Discovery & Research
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Pharmaceutical and Biotechnology Companies
  • 10.3.2. Academic & Research Institutes
  • 10.3.3. Others
• 10.4. Market Analysis, Insights, and Forecast - By Country/Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
  • 11.2.1. Thermo Fisher Scientific Inc.
  • 11.2.2. New England Biolabs
  • 11.2.3. Danaher Corporation
  • 11.2.4. Fortis Life Sciences, LLC.
  • 11.2.5. Promega Corporation
  • 11.2.6. Bio-Rad Laboratories, Inc.
  • 11.2.7. BioCat GmbH
  • 11.2.8. Takara Bio Inc.
  • 11.2.9. Agilent Technologies, Inc.